Most of the few approved drugs such as the acetylcholinesterase (AChE) inhibitors donepezil, rivastigmine, and galantamine, and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine for AD [6]; dopaminergic drugs such as levodopa for PD [7]; riluzole and edaravone for ALS [8]; and tetrabenazine and deutetrabenazine to reduce chorea in HA [9] only provide symptom management, while disease-modifying drugs are still in their infancy. This evidence concerns the gene ACHE and choreatic disease.